Nota clínicaOsteonecrosis del maxilar en pacientes con mieloma múltiple durante y después del tratamiento con ácido zoledrónicoOsteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid
Referencias bibliográficas (20)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic
J Oral Maxillofac Surg
(2003)- et al.
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
J Oral Maxillofac Surg
(2004) - et al.
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition
J Am Dent Assoc
(2005) Guidelines on the diagnosis and management of multiple myeloma 2005
Br J Haematol
(2005)- et al.
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma
J Clin Oncol
(2002) - et al.
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group
N Engl J Med
(1996) - et al.
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy
Drugs
(2003) Bisphosphonates and oral cavity avascular bone necrosis
J Clin Oncol
(2003)- et al.
Bisphosphonates and osteonecrosis of the jaw
Med J Aust
(2005) - et al.
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases
J Oral Pathol Med
(2005)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2006 Elsevier España S.L. All rights reserved.